Expression of DLL4 and ephrinB2 in KLN205 and LLC tumors. (A) Expression of DLL4 in subcutaneous KLN205 and LLC tumors was detected by RT-PCR (left) and Western blotting (right). (B) Representative immunohistochemical staining of factor VIII–related antigen, DLL4, and ephrinB2. Data were obtained from serial sections of the same area in both KLN205 and LLC tumors. (C) Western blotting of ephrinB2 in KLN205 (left) and LLC (right) tumors. (D) The relative expression of ephrinB2 was measured by densitometric analysis in KLN205 tumors (left) and LLC tumors (right). The results are expressed as the ratio of the amount of ephrinB2 protein to the amount of β-actin. Data are mean plus or minus SE (n = 7 per group). *P < .05 versus control by Student unpaired t test (left) or 1-way ANOVA with Fisher least-significant-difference test (right).